CDT Equity Inc.
CDT · XNASCIK 1896212fmd_0HFHS57M1FSWFH2EZWFSJHERQ1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Jun 30, 2026, 19 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Realized investment gains (losses) | (0) | – | – | – |
| Research and development | 0 | 0 | 3 | 5 |
| Total operating expenses | 3 | 5 | 15 | 37 |
| Operating income | (3) | (5) | (15) | (37) |
| Interest expense | 0 | 0 | 0 | 0 |
| Interest and investment income | 2 | 0 | – | – |
| Other non-operating income (expense) | (2) | 5 | (2) | (2) |
| Income before taxes | 1 | (1) | (18) | (39) |
| Income tax expense | 0 | – | – | – |
| Net income from continuing operations | 0 | – | – | – |
| Net income | (5) | (1) | (18) | (39) |
| Net income to common shareholders | (5) | (1) | (18) | (39) |